PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Apomorphine hydrochloride - Parkinson's disease
PAD Profile : Apomorphine hydrochloride - Parkinson's disease
Keywords :
PD
Brand Names Include :
Apo-go, Dacepton, Apo-Go POD
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
01 November 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) have reviewed and agreed the updated apomorphine AMBER shared care document.
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism